ABBV News and Press, AbbVie Inc. From 06/13/24

2024-06-13 13:54:33 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? Cerevel Therapeutics gains after AbbVie says making good progress with FTC AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug ...

2024-06-13 08:25:53 ET More on AbbVie AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now Cerevel T...

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease PR Newswire - Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NOR...

2024-06-12 19:12:07 ET AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & C...

2024-06-12 11:30:31 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug Seeking Alpha’s Quant Rating on Cerevel Therapeutics Historical ear...

BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients PR Newswire For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap ...

2024-06-11 04:33:48 ET More on Alvotech Alvotech (ALVO) Q1 2024 Earnings Call Transcript Alvotech 2024 Q1 - Results - Earnings Call Presentation Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech enters $965M refinancing agreement ...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-10 23:55:53 ET Summary REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, a...

2024-06-10 13:25:30 ET Summary Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye dis...